Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Pembrolizumab and BCG in NMIBC
NCT02808143Phase 1Completed
- Sponsor
- Northwestern University
- Start
- Feb 2017
- Primary completion
- May 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Northwestern University. Primary endpoint: Maximum Tolerated Dose at 9 weeks. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02808143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808143.